Berenguer et al. have discovered a novel mechanism for EV uptake, in which the chemokine receptor CCR8 on cells interacts with glycans on the surface of EVs as well as the soluble ligand CCL18. Based on this, they demonstrate that peptide MC148 and small molecule inhibitor R243, two inhibitors for CCR8, could inhibit EV uptake by GBM cells and resensitize them to TMZ.[245] EVs from bone marrow stromal cells are internalized by MM cells and reduce their chemosensitivity to bortezomib. The gene discussed is CCR8; the disease is glioblastoma.